Breakthrough drug can cut chances of lung cancer returning by a third when used alongside chemotherapy and surgery...so why have NHS chiefs rejected it?

Durvalumab has been shown in trials to be effective at curing patients with the most common form of lung cancer when combined in the early stages of the disease alongside chemotherapy.

  Health   Sep 1, 2024   0   25  Add to Reading List
Breakthrough drug can cut chances of lung cancer returning by a third when used alongside chemotherapy and surgery...so why have NHS chiefs rejected it?


Click the link to join the registration on WhatsApp: https://chat.whatsapp.com/KThkuZlWaTcCu3iJHGBmLM


Click the link to join the registration on WhatsApp: https://chat.whatsapp.com/KThkuZlWaTcCu3iJHGBmLM


Click the link to join the registration on WhatsApp: https://chat.whatsapp.com/KThkuZlWaTcCu3iJHGBmLM
Durvalumab has been shown in trials to be effective at curing patients with the most common form of lung cancer when combined in the early stages of the disease alongside chemotherapy.
Read Original   

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow